Adial Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for the treatment of addiction and related disorders
The company is primarily engaged in the research and clinical development of its lead product candidate, which aims to reduce the risk of relapse in patients with alcohol use disorder. Adial utilizes a patient population-centric approach to address significant unmet medical needs in substance use disorders through its proprietary technology and scientific expertise. By leveraging partnerships and conducting clinical trials, Adial is committed to advancing solutions that improve the lives of individuals affected by addiction.
Adial Pharmaceuticals completes PK study for AD04 in AUD, meeting FDA requirements and preparing for Phase 3 trial. Data supports 505(b)(2) application.
Adial Pharmaceuticals secures a new patent allowance for AD04, enhancing its precision medicine approach for treating alcohol use disorder. Topline results from AD04's latest study are expected in Q4 2024.
Adial Pharmaceuticals has partnered with Boudicca Dx to advance the regulatory and technical strategy for its companion diagnostic test for AD0 for Alcohol Use Disorder. This collaboration is pivotal for Adial's upcoming Phase 3 trial.
Adial Pharmaceuticals announces the completion of the pharmacokinetics study dosing for AD04, their lead investigational treatment for Alcohol Use Disorder in heavy drinking patients. Topline results expected in Q4 2024 will inform Phase 3 clinical trial plans.
Adial Pharmaceuticals progresses to the second cohort in the AD04 pharmacokinetics study for Alcohol Use Disorder. This study, involving up to 30 healthy volunteers, will provide critical insights for the upcoming Phase 3 trial. Topline results expected Q4 2024.
Adial Pharmaceuticals publishes Phase 3 ONWARD study results in the European Journal of Internal Medicine. The study reveals AD04 significantly reduces heavy drinking days, with adverse events matching the placebo.
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Today the MicroCap Rodeo - Spring into Summer will take place in-person on Thursday, June 6th, 2024 and host the executive management teams of 25 microcap companies.
Adial Pharmaceuticals starts dosing in pharmacokinetics study of AD04 for Alcohol Use Disorder in heavy drinking patients. Topline results in early Q4 2024.
